<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04209933</url>
  </required_header>
  <id_info>
    <org_study_id>KY20192146-C-1</org_study_id>
    <nct_id>NCT04209933</nct_id>
  </id_info>
  <brief_title>Helicobacter Pylori Eradication With Different Bismuth Quadruple Therapies</brief_title>
  <official_title>Comparison of Efficacy of Bismuth Potassium Citrate, Pectin Bismuth Capsules, and Pectin Bismuth Granules in the Treatment of Helicobacter Pylori (Hp) First-line Quadruple Regimen: a Multicenter, Randomized, Prospective, Comparative Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xijing Hospital of Digestive Diseases</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xijing Hospital of Digestive Diseases</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to compare efficacy and safety of bismuth-containing quadruple therapy（with&#xD;
      rabeprazole amoxicillin clarithromycin）of different kinds of bismuth（Bismuth potassium&#xD;
      citrate, pectin bismuth capsules, pectin bismuth particles）in H. pylori first-line&#xD;
      eradication. It is hypothesized that different bismuth containing quadruple therapies have&#xD;
      comparable eradication efficacy and safety. Patients with confirmed H. pylori positive status&#xD;
      will be randomized to one of the treatments described above. At week 2and 6 follow-up visits,&#xD;
      a urea breath test(UBT) will be performed to confirm eradication.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will include three phases: screening, treatment and follow-up.Screening: this phase&#xD;
      will last a maximum of 28 days and subjects eligibility will be evaluated after informed&#xD;
      consent signature. Endoscopy and Urea Breath test will be performed in addition to the&#xD;
      baseline routine evaluations.Treatment: Subjects are randomly assigned to treatment and will&#xD;
      be treated for 14 days. A randomization visit will take place on Day 0 and an&#xD;
      end-of-treatment visit will take place between day 12 and 14.Follow-up: includes two visits.&#xD;
      approximately 14 days of treatment and 28 days after the end of treatment. Eradication of H.&#xD;
      Pylori will be confirmed through urea breath test(UBT).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 25, 2020</start_date>
  <completion_date type="Actual">August 30, 2020</completion_date>
  <primary_completion_date type="Actual">August 1, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>helicobacter pylori eradication</measure>
    <time_frame>28 days after treatment]</time_frame>
    <description>The primary end point of this study is H.pylori eradication,established by negative [13C] urea breath test 28 days after the end of eradication.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>symptoms effective rates</measure>
    <time_frame>14 days of treatment, and 28 days after treatment</time_frame>
    <description>symptoms effective rates Evaluation effective rate of symptoms 2 weeks of treatment and 4 weeks after the end of treatment. Symptom effective rate =#total score before treatment - total score after treatment#/total score before treatment x100%. Total score = frequency + severity.Frequency score is calculated by all the frequency of heartburn, reflux, abdominal pain, and flatulence. Severity is accumulated by the degree of symptoms described above, which is divided to 4 degree as 0 presenting none, and 3presenting most severe</description>
  </secondary_outcome>
  <other_outcome>
    <measure>adverse events</measure>
    <time_frame>14 days of treatment, and 28 days after treatment</time_frame>
    <description>Participants with Adverse Events as a Measure of Safety and Tolerability.The common side effects of the study include headache, dizziness, skin rash, other gastrointestinal disorders, pyrexia, cough and back pain.</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">240</enrollment>
  <condition>Gastric Cancer</condition>
  <condition>Helicobacter Pylori Infection</condition>
  <condition>Bismuth</condition>
  <arm_group>
    <arm_group_label>Bismuth potassium citrate containing quadruple therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bismuth potassium citrate 220 mg,rabeprazole 10 mg, amoxicillin 1000mg, and clarithromycin 500 mg by mouth,twice daily for 14 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Colloidal pectin bismuth capsules containing quadruple therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Colloidal pectin bismuth capsules 200 mg,rabeprazole 10 mg, amoxicillin 1000mg, and clarithromycin 500 mg by mouth,twice daily for 14 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Colloidal pectin bismuth particles A quadruple therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Colloidal pectin bismuth particles 150 mg,rabeprazole 10 mg, amoxicillin 1000mg, and clarithromycin 500 mg by mouth,twice daily for 14 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Colloidal pectin bismuth particles B quadruple therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Colloidal pectin bismuth particles 300 mg,rabeprazole 10 mg, amoxicillin 1000mg, and clarithromycin 500 mg by mouth,twice daily for 14 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bismuth potassium citrate containing quadruple therapy</intervention_name>
    <description>Bismuth potassium citrate:given for 14 days at a dose of bismuth potassium citrate 220 mg 0 BID,rabeprazole 10 mg BID, amoxicillin 1000 mg BID, and clarithromycin 500 mg BID</description>
    <arm_group_label>Bismuth potassium citrate containing quadruple therapy</arm_group_label>
    <arm_group_label>Colloidal pectin bismuth capsules containing quadruple therapy</arm_group_label>
    <arm_group_label>Colloidal pectin bismuth particles A quadruple therapy</arm_group_label>
    <arm_group_label>Colloidal pectin bismuth particles B quadruple therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Colloidal pectin bismuth capsules containing quadruple therapy</intervention_name>
    <description>Bismuth potassium citrate:given for 14 days at a dose of Colloidal pectin bismuth capsules 200 mg 0 BID,rabeprazole 10 mg BID, amoxicillin 1000 mg BID, and clarithromycin 500 mg BID</description>
    <arm_group_label>Bismuth potassium citrate containing quadruple therapy</arm_group_label>
    <arm_group_label>Colloidal pectin bismuth capsules containing quadruple therapy</arm_group_label>
    <arm_group_label>Colloidal pectin bismuth particles A quadruple therapy</arm_group_label>
    <arm_group_label>Colloidal pectin bismuth particles B quadruple therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Colloidal pectin bismuth particles A quadruple therapy</intervention_name>
    <description>Bismuth potassium citrate:given for 14 days at a dose of Colloidal pectin bismuth particles 150 mg BID,rabeprazole 10 mg BID, amoxicillin 1000 mg BID, and clarithromycin 500 mg BID</description>
    <arm_group_label>Bismuth potassium citrate containing quadruple therapy</arm_group_label>
    <arm_group_label>Colloidal pectin bismuth capsules containing quadruple therapy</arm_group_label>
    <arm_group_label>Colloidal pectin bismuth particles A quadruple therapy</arm_group_label>
    <arm_group_label>Colloidal pectin bismuth particles B quadruple therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Colloidal pectin bismuth particles B quadruple therapy</intervention_name>
    <description>Bismuth potassium citrate:given for 14 days at a dose of Colloidal pectin bismuth particles 300 mg BID,rabeprazole 10 mg BID, amoxicillin 1000 mg BID, and clarithromycin 500 mg BID</description>
    <arm_group_label>Bismuth potassium citrate containing quadruple therapy</arm_group_label>
    <arm_group_label>Colloidal pectin bismuth capsules containing quadruple therapy</arm_group_label>
    <arm_group_label>Colloidal pectin bismuth particles A quadruple therapy</arm_group_label>
    <arm_group_label>Colloidal pectin bismuth particles B quadruple therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age between 18~75,both gender.&#xD;
&#xD;
          -  Patients with upper gastrointestinal symptoms and with documented H.pylori infection.&#xD;
&#xD;
          -  Patients are willing to receive eradication treatment.&#xD;
&#xD;
          -  Women are eligible if they are not pregnant or nursing, and if they are of&#xD;
             childbearing potential they are required to use medically acceptable contraception for&#xD;
             the duration of the study and 30 days thereafter.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients are excluded if they have previously used antibiotics to eradicate adequately&#xD;
             recorded infection with H. pylori.&#xD;
&#xD;
          -  Contraindications to study drugs.&#xD;
&#xD;
          -  Substantial organ impairment, severe or unstable cardiopulmonary or endocrine disease.&#xD;
&#xD;
          -  Constant use of anti-ulcer drugs ( including taking proton-pump.inhibitors(PPI) within&#xD;
             2 weeks before the [13C] urea breath test),antibiotics or bismuth complexes (more than&#xD;
             3 times /1 month before screening).&#xD;
&#xD;
          -  Patients were diagnosed with gastroduodenal ulcer and MALTlymphoma.&#xD;
&#xD;
          -  Pregnant or lactating women.&#xD;
&#xD;
          -  Underwent upper gastrointestinal Surgery.&#xD;
&#xD;
          -  Patients with Barrett esophageal or highly atypical hyperplasia, have symptom of&#xD;
             dysphagia.&#xD;
&#xD;
          -  Evidence of bleeding or iron efficiency anemia.- Page 3 of 4 [DRAFT] -&#xD;
&#xD;
          -  A history of malignancy.&#xD;
&#xD;
          -  Drug or alcohol abuse history in the past 1 year.&#xD;
&#xD;
          -  Systemic use of corticosteroids, non steroidal anti-inflammatory drugs,anticoagulants,&#xD;
             platelet aggregation inhibitors (except the use of aspirin for less than 100 mg/d).&#xD;
&#xD;
          -  Patients who has psychological problem or poor compliance.&#xD;
&#xD;
          -  Enrolled in other clinical trials in the past 3 months.&#xD;
&#xD;
          -  Refuse to sign informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Xijing Hosipital of Digestive Disease</name>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <zip>710032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>December 13, 2019</study_first_submitted>
  <study_first_submitted_qc>December 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 24, 2019</study_first_posted>
  <last_update_submitted>April 6, 2021</last_update_submitted>
  <last_update_submitted_qc>April 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Xijing Hospital of Digestive Diseases</investigator_affiliation>
    <investigator_full_name>Yongquan Shi</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Potassium Citrate</mesh_term>
    <mesh_term>Bismuth</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

